Immunocore Holdings PLC Form 4 insider transactions

Director Peter John Ratcliffe was granted 27,492 share options in Immunocore Holdings plc.

Director Kristine Peterson was granted 27,492 stock options in Immunocore Holdings plc as part of a standard equity incentive.

Director William Pao was granted 27,492 stock options in Immunocore Holdings plc with an exercise price of $28.52.

Director Siddharth Kaul was granted 27,492 stock options in Immunocore Holdings plc as part of an equity compensation award.

Director Roy Herbst was granted 27,492 stock options in Immunocore Holdings plc as part of an equity compensation award.

Immunocore Holdings plc director John Irving Bell was granted 27,492 stock options as part of a standard equity compensation award.

Immunocore Holdings plc's Chief Financial Officer, Travis Alan Coy, was granted 33,353 restricted share units and 95,637 employee share options.

Immunocore Holdings plc CEO Bahija Jallal reported the vesting of restricted share units, subsequent sale of shares to cover tax liabilities, and the grant of new equity awards.

Immunocore's SVP of Finance and CAO, John Goll, reported new equity awards and a tax-related share sale.

Immunocore Holdings plc's Chief HR Officer, Tina Amber St Leger, sold 1,000 ordinary shares for tax purposes following the vesting of restricted share units.

Immunocore's Head of R&D, David M. Berman, sold a portion of his vested ordinary shares to cover tax liabilities following the exercise of restricted share units.

Immunocore's Head of R&D, David M. Berman, exercised stock options and sold a total of 31,913 ordinary shares for approximately $1.28 million under a pre-arranged trading plan.

Immunocore's Head of R&D, David M. Berman, exercised and immediately sold a total of 74,925 ordinary shares through a pre-arranged 10b5-1 trading plan.

Immunocore Holdings plc's Head of R&D, David M. Berman, executed pre-planned sales of ordinary shares following the exercise of employee stock options.

Immunocore's Head of R&D, David M. Berman, executed stock options and subsequently sold the acquired shares for a profit, as per a pre-arranged 10b5-1 trading plan.

Immunocore Holdings plc's Head of R&D, David M. Berman, executed pre-planned sales of ordinary shares following option exercises in mid-September 2025.

Immunocore's Head of R&D, David M. Berman, executed a pre-planned sale of company shares following the exercise of employee stock options.

Director Peter John Ratcliffe acquired 26,198 share options in Immunocore Holdings plc on May 15, 2025.

Director William Pao receives share options for Immunocore Holdings plc.

Director Roy Steven Herbst receives share options in Immunocore Holdings plc.

Kristine Peterson, a director at Immunocore Holdings plc, acquired share options exercisable for 26,198 ordinary shares.

Director Siddharth Kaul receives share options in Immunocore Holdings plc.

Director John Irving Bell acquired share options in Immunocore Holdings plc on May 15, 2025.

Baker Bros. Advisors LP reports the acquisition of non-qualified share options for Immunocore Holdings director Ranjeev Krishana, exercisable into ordinary shares, as part of the company's 2021 Equity Incentive Plan.

Baker Bros. Advisors and related entities report transactions in Immunocore Holdings plc securities, including purchases of American Depositary Shares (ADS) and sales of convertible notes, while also agreeing to disgorge short-swing profits.

Director William Pao reports the acquisition of share options in Immunocore Holdings plc.

Tina Amber St Leger, Chief HR Officer of Immunocore Holdings plc, received stock options and restricted share units (RSUs) on February 17, 2025, according to a Form 4 filing with the SEC.

John Goll, SVP, Finance & CAO of Immunocore Holdings plc, reports the acquisition of stock options and restricted share units.

David M. Berman, Head of R&D at Immunocore Holdings PLC, was granted stock options and restricted share units on February 17, 2025, according to a Form 4 filing.

CEO of Immunocore Holdings, Bahija Jallal, receives stock options and restricted share units as part of compensation.